Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05029960 · ClinicalTrials.gov registry record · Early Phase 1
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
A Early Phase 1 study of Brain Tumor, sponsored by University of Rochester.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05029960: Active Early Phase 1 study of Brain Tumor, sponsored by University of Rochester.
NCT05029960 is a Early Phase 1 study of Brain Tumor that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 30 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05029960, a Early Phase 1 study of Brain Tumor, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Primary Outcome
Evaluate adverse events
Conditions Studied
Interventions
- DRUG Brivaracetam
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2025-08-31 |
| Phase | Early Phase 1 |
What the registry record for NCT05029960 still lists
NCT05029960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Brivaracetam is the first listed.
NCT05029960 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05029960 about?
NCT05029960 is a clinical study titled "Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas". The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
What is the current status of trial NCT05029960?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2022-05-17. Estimated completion is 2025-08-31.
What conditions does trial NCT05029960 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT05029960?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT05029960?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05029960 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05029960's enrollment target sits among peer trials
30 46th of 69 higher than 20 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
ACTIVE NOT RECRUITING · Early Phase 1
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
COMPLETED · Early Phase 1
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI